2 minute read | June.25.2026
Français: Orrick conseille Carvolix dans le cadre de son opération de financement de 10 millions d’euros
Carvolix has completed a €10 million financing transaction, marking an important milestone in its ongoing €30 million program. This capital increase reflects renewed support from strategic shareholders and positions the company for continued growth.
Orrick advised Carvolix in connection with the financing.
Carvolix (formerly Affluent Medical) is a French commercial- and clinical-stage medical technology company, founded by Truffle Capital. Carvolix specializes in AI-driven mini-robots and biomimetic implants for the treatment of structural heart diseases and strokes.
The proceeds will support the commercialization of Tavipilot in the United States and the advancement of Carvolix's strategic regulatory and clinical developments across its pipeline (Tavipilot, Kalios, Artus, Artedrone, Mitrapilot). A portion of the proceeds will repay bridge financing from Truffle Capital. The company is also negotiating a venture debt facility of approximately €25 million with leading European venture debt funds, which would extend its cash runway beyond 12 months.
The Orrick team is led by Vianney Toulouse (Partner) and includes Mathilde Duchamp from the M&A/Capital Markets team dedicated to Life Sciences, under the supervision of Alain Decombe (Senior Partner).